Skip to main content
Alberto Pappo, MD
Alberto Pappo, MD

Alberto Pappo, MD

Member, St. Jude Faculty

  • Director, Solid Tumor Division
  • Co-Leader, Developmental Biology & Solid Tumor Program
  • Alvin Mauer Endowed Chair




MD – Medical School, Universidad Anahuac, Mexico City (1984)
Residency – The University of Texas Health Science Center, San Antonio, Texas (1985-1988)
Fellowship – Children’s Medical Center of Dallas and The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas (1988-1991)
Clinical Fellowship – American Cancer Society (1989-1990)

Research Interests

Development of novel therapies for pediatric solid tumors with special interest in:

  • Pediatric melanoma
  • Soft tissue sarcomas
  • Pediatric gastrointestinal stromal tumors

Selected Publications

Pui CH, Pei D, Pappo AS, Howard SC, Cheng C, Sandlund JT, Furman WL, Ribeiro RC, Spunt SL, Rubnitz JE, Jeha S, Hudson MM, Kun LE, Merchant TE, Kocak M, Broniscer A, Metzger ML, Downing JR, Leung W, Evans WE, Gajjar A. Treatment Outcomes in Black and White Children With Cancer: Results From the SEER Database and St. Jude Children’s Research Hospital, 1992 Through 2007. J Clin Oncol 30:2005-2012, 2012. PMCID: PMC3383176.

Pappo AS, Armstrong GT, Liu W, Srivastava DK, McDonald A, Leisenring WM, Hammond S, Stovall M, Neglia JP, Robison, LL. Melanoma as a subsequent neoplasm in adult survivors of childhood cancer: A report from the childhood cancer survivor study. Pediatr Blood Cancer Aug 8, 2012. Epub ahead of print. PMCID: PMC3538914.

Walterhouse DO, Meza JL, Breneman JC, Donaldson SS, Hayes-Jordan A, Pappo AS, Arndt C, Raney RB, Meyer WH, Hawkins DS. Local control and outcome in children with localized vaginal rhabdomyosarcoma: A report from the Soft Tissue Sarcoma committee of the Children's Oncology Group. Pediatr Blood and Cancer 57:76-83, 2011. PMCID: PMC3459820.

Pappo AS, Krailo M, Rodriguez-Galindo C, Reaman G. Infrequent tumor initiative of the Children’s Oncology Group: Initial lessons learned and their impact on future plans. J Clin Oncol 28:5011-5016, 2010. PMCID: PMC3539303.

Katzenstein H, Chang K, Krailo M, Chen Z, Finegold M, Rowland J, Reynolds M, Pappo A, London W, Malogolowkin M. Amifostine does not prevent platinum-induced hearing loss associated with the treatment of children with hepatoblastoma: A report of the Intergroup Hepatoblastoma Study P9645 as a part of the Children’s Oncology Group. Cancer 115:5828-35, 2009. PMCID: PMC2795100.

Qualman S, Lynch J, Bridge J, Parham D, Teot L, Meyer W, Pappo A. Prevalence and clinical impact of anaplasia in childhood rhbadomyosarcoma. Cancer 113:3242-3247, 2008. PMCID: PMC2727712.

Pappo AS, Lyden E, Breitfeld P, Donaldson SS, Wiener E, Parham D, Crews KR, Houghton P, Meyer WH. Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: The Children’s Oncology Group. J Clin Oncol 25:362-369, 2007.

Meza JL, Anderson J, Pappo AS, Meyer WH. Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on Intergroup Rhabdomyosarcoma Studies III and IB: the Children’s Oncology Group. J Clin Oncol 24:3844-3851, 2006.

Shah NC, Gerstle T, Stuart M, Winter C, Pappo A. Use of sentinel lymph node biopsy and high-dose interferon in pediatric patients with high-risk melanoma: The Hospital for Sick Children experience. J Pediatr Hematol Oncol 28:496-500, 2006.

Ramphal R, Pappo A, Zielenska M, Grant R, Ngan BY. Pediatric renal cell carcinoma. Clinical, pathologic and molecular abnormalities associated with the members of the MiT transcriptor factor family. Am J Clin Pathol 126, 2006.

Lager JJ, Lyden ER, Anderson JR, Pappo AS, Meyer WH. Pooled analysis of phase II window studies in children with contemporary high-risk metastatic Rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. J Clin Oncol 24:3415-3422, 2006.

Navid F, Santana VM, Billups CA, Merchant TE, Furman WL, Spunt SL, Cain AM, Rao BN, Hale GA, Pappo AS. Concomitant administration of vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide for high risk sarcoma. Cancer 106:1846-1856, 2006.

Price VE, Zielenska M, Chilton-Macneill S, Smith C, Pappo AS. Clinical and molecular characteristics of pediatric gastrointestinal stromal tumors (GISTs). Pediatr Blood Cancer 45:20-24, 2005.

Navid F, Furman WL, Fleming M, Rao BN, Kovach S, Billups CA, Cain AM, Amonette R, Jenkins JJ,Pappo AS. The feasibility of adjuvant interferon aplha-2b in children with high-risk melanoma.Cancer 103:780-787, 2005.

Pappo AS, Devidas M, Jenkins J, Rao B, Marcus R, Thomas P, Gebhardt M, Pratt C, Grier HE. Phase II trial of neoadjuvant vincristine, ifosfamide, and doxorubicin with granulocyte colony-stimulating factor support in children and adolescents with advanced stage nonrhabdomyosarcomatous soft tissue sarcomas: A Pediatric Oncology Group Study. J Clin Oncol 18:2005.

Rodriguez-Galindo C, Wofford M, Castleberry RP, Swanson GP, London WB, Fontanesi J, Pappo AS, Douglass EC. Preradiation chemotherapy with methotrexate, cisplatin, 5_Fluorouracil, and leucovorin for pediatric nasopharyngeal carcinoma: results of Pediatric Oncology Group (now Children’s Oncology Group) study 9486. Cancer 103:850-857, 2005.

Sung L, Anderson JR, Donaldson SS, Spunt SL, Crist WM, Pappo AS. Late events occurring five years or more after successful therapy for childhood rhabdomyosarcoma: a report from the Soft Tissue sarcoma Committee of the Children’s Oncology Group. Eur J Cancer 40:1878-1885, 2004.

Cypriano MS, Jenkins JJ, Pappo AS, Rao BN, Daw NC. Pediatric gastrointestinal stromal tumors and leiomyosarcoma. Cancer 101:39-50, 2004.

Sung L, Anderson JR, Arndt C, Raney RB, Meyer WH, Pappo AS Neurofibromatosis in children with rhabdomyosarcoma: A report from the Intergroup Rhabdomyosarcoma Study IV. J Pediatr 144:666-668, 2004.

Ocku FM, Munsell M, Treuner J, Mattke A, Pappo A, Cain A, Ferrari A, Casanova M, Ozkan A, Raney B. Synovial sarcoma of childhood and adolescence: A multicenter, multivariate analysis of outcome.J Clin Oncol 21:1602-1611, 2003.

Breneman an JC, Lyden E, Pappo AS, Link MP, Anderson JR, Parham DM, Qualman SJ, Wharam MD, Donaldson SS, Maurer HM, Meyer WH, Baker KS, Paidas CN, Crist WM. Prognostic factors and clinical outcome in children and adolescents with metastatic rhabdomyosarcoma: A report from the Intergroup Rhabdomyosarcoma Study IV. J Clin Oncol 21:78-84, 2003.

Hill DA, Riedley SE, Patel AR, Shurtleff SA, Hyer J, Cain AM, Billups CA, Downing JR, Pappo AS. Real time polymerase chain reaction as an aid for the detection of SYT-SSX1 and SYT-SSX2 transcripts in fresh and archival pediatric synovial sarcoma specimens: Report of 25 cases from St Jude Children’s Research Hospital. Pediatr Dev Pathol 6:24-34, 2002.

Last update: February 2013